🇺🇸 FDA
Patent

US 8883841

Oncogenic ras-specific cytotoxic compound and methods of use thereof

granted A61KA61K31/404A61P

Quick answer

US patent 8883841 (Oncogenic ras-specific cytotoxic compound and methods of use thereof) held by The Board of Regents of the University of Texas System expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
52
CPC classes
A61K, A61K31/404, A61P, A61P31/12, A61P35/00